UFP Technologies, Inc. (UFPT) is a publicly traded company in the Healthcare — Medical - Devices industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
UFP Technologies, Inc. specializes in the engineering and custom fabrication of components, subassemblies, finished products, and packaging, primarily utilizing advanced foams, films, and plastics. A significant portion of its business is dedicated to the medical sector, where its single-use and single-patient devices and parts are integral to a broad spectrum of applications, including general medical devices, disposable wound care, infection control, minimally invasive surg...
Is UFP Technologies, Inc. stock overvalued or undervalued in 2026?
UFP Technologies, Inc. (UFPT) trades at 30.7× earnings (P/E), in line with the median of the 249 healthcare companies over $2bn in Kaplio's universe. At the decade median (27.3×) $253 (-11 %); at its sector median (30.7×) $284 (0 %).
Kaplio overview: UFP Technologies, Inc.
Market cap $2B · 52 weeks $185 – $335 (15 % below the high) · P/E 30.7× · 2027 est. P/E 26.2× · Dividend none · Next earnings November 3, 2026 · expected EPS $2.49 · Closing price, Oct 30 · accounts published Aug 3.
- Valuation: P/E 30.7× (fairly priced).
- Business: ROIC 13 % (fair).
- Balance sheet: Net debt/EBITDA 1.2× (solid).
- Earnings: 8 of 8 (on track).
What would it be worth at its usual multiples?
At the decade median (27.3×) $253 (-11 %); at its sector median (30.7×) $284 (0 %). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.
What matters in pharma: 5 of 7 pass
- R&D / Revenue 0.0 %, fails.
- Gross margin 28.3 %, fails.
- 5y EPS growth 37.8 %, passes.
- FCF / Net Income 115.6 %, passes.
- ROIC 12.7 %, passes, near the threshold.
- Net debt / EBITDA 1.2×, passes.
- P/E vs own 10y history 30.7×, passes.
Against its peers (reference peers) — UFP Technologies, Inc.: P/E 30.7×; EV/EBITDA 20.1×; ROIC 12.7 %; $2.2B. GE HealthCare Technologies Inc. (P/E 20.0×; EV/EBITDA 13.2×; ROIC 7.5 %; $34.6B), Medtronic Plc (P/E 23.8×; EV/EBITDA 14.7×; ROIC 6.4 %; $123B), TransMedics Group, Inc. (P/E 17.1×; EV/EBITDA 20.6×; ROIC 5.9 %; $2.3B).
Expensive or cheap against its last ten years?
P/E at each close: today 30.7× · median 27.3× · minimum 13.2× · maximum 60.8× · cheap below 24.4× · expensive above 37.5×. It has been cheaper than today 63% of the time over its last ten years.
Profitability
| Return on Equity | 16.72% |
| Return on Invested Capital | 12.65% |
| Return on Assets | 10.60% |
| Gross Margin | 28.50% |
| Operating Margin | 15.25% |
| Net Margin | 11.45% |
Financial Health
| Debt / Equity | 0.29 |
| Current Ratio | 3.00 |
| Piotroski F-Score | 7 |
| Altman Z-Score | 6.62 |
Price Performance
| 1 month | -5.39% |
| 3 months | -15.03% |
| Year-to-date | +28.14% |
| 1 year | +47.68% |
| 3 years | +98.71% |
| 5 years | +363.43% |
| 10 years | +1044.87% |
Related companies: GEHC · MDT · ABT · 0Y6X.L · SYK · 0R2S.L · 0HOY.L · BSX
Explore sector: Healthcare · Medical - Devices
More sections of UFPT: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks